Literature DB >> 10229324

Differences in phosphorylation of the IL-2R associated JAK/STAT proteins between HTLV-I(+), IL-2-independent and IL-2-dependent cell lines and uncultured leukemic cells from patients with adult T-cell lymphoma/leukemia.

Q Zhang1, B Lee, M Korecka, G Li, C Weyland, S Eck, A Gessain, N Arima, S R Lessin, L M Shaw, S Luger, M Kamoun, M A Wasik.   

Abstract

To determine activation status of the IL-2R-associated (Jak/STAT) pathway in the HTLV-I infected cells, we examined tyrosine phosphorylation of Jak3, STAT3, and STAT5 in several HTLV-I(+) T-cell lines and in uncultured leukemic T cells isolated from patients with adult T-cell lymphoma/leukemia (ATLL). Constitutive basal phosphorylation of Jak3 and, usually, STAT3 and STAT5 was detected in all four IL-2-independent cell lines tested, but in none of the three IL-2-dependent cell lines. Similarly, there was no detectable basal phosphorylation of Jak3 and STAT5 in the leukemic cells from ATLL patients (0/8 and 0/3, respectively). However, stimulation with IL-2 resulted in Jak3 and STAT5 phosphorylation in both leukemic ATLL cells and IL-2-dependent lines. Furthermore, expression of SHP-1 phosphatase which is a negative regulator of cytokine receptor signaling, was lost in most IL-2 independent cell lines (3/4) but not in the leukemic ATLL cells (0/3). Finally, the HTLV-I(+) T-cell lines (313) but not the control, HTLV-I(-) T-cell lines were resistant to rapamycin and its novel analog RAD. We conclude that (1) HTLV-I infection per se does not result in a constitutive phosphorylation of the Jak3, STAT3, and STAT5 proteins; (2) malignant transformation in at least some cases of ATLL does not require the constitutive, but may require IL-2-induced, activation of the IL-2R Jak/STAT pathway; and (3) there are major differences in T-cell immortalization mechanism(s) which appear to involve SHP-1 and target molecules for rapamycin and RAD.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10229324     DOI: 10.1016/s0145-2126(98)00173-8

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  10 in total

1.  Comparative genome-scale analysis of gene expression profiles in T cell lymphoma cells during malignant progression using a complementary DNA microarray.

Authors:  S Li; D T Ross; M E Kadin; P O Brown; M A Wasik
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

2.  Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter.

Authors:  Q Zhang; P N Raghunath; E Vonderheid; N Odum; M A Wasik
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

Review 3.  Human T-lymphotropic virus proteins and post-translational modification pathways.

Authors:  Carlo Bidoia
Journal:  World J Virol       Date:  2012-08-12

4.  Association of SRC-related kinase Lyn with the interleukin-2 receptor and its role in maintaining constitutive phosphorylation of JAK/STAT in human T-cell leukemia virus type 1-transformed T cells.

Authors:  Maureen Shuh; Barry A Morse; Gisela Heidecker; David Derse
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

5.  The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders.

Authors:  M Majewski; M Korecka; P Kossev; S Li; J Goldman; J Moore; L E Silberstein; P C Nowell; W Schuler; L M Shaw; M A Wasik
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

6.  Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma.

Authors:  T Kameda; K Shide; H K Shimoda; T Hidaka; Y Kubuki; K Katayose; Y Taniguchi; M Sekine; A Kamiunntenn; K Maeda; K Nagata; T Matsunaga; K Shimoda
Journal:  Int J Hematol       Date:  2010-08-10       Impact factor: 2.490

7.  Negative regulation of the SH2-homology containing protein-tyrosine phosphatase-1 (SHP-1) P2 promoter by the HTLV-1 Tax oncoprotein.

Authors:  Jihua Cheng; Andre R Kydd; Koichi Nakase; Kristin M Noonan; Akikazu Murakami; Hong Tao; Markryan Dwyer; Chen Xu; Quan Zhu; Wayne A Marasco
Journal:  Blood       Date:  2007-05-31       Impact factor: 22.113

8.  Expression of HIF-2α and VEGF in Cervical Squamous Cell Carcinoma and Its Clinical Significance.

Authors:  Lixia Zhang; Qiang Chen; Jing Hu; Yue Chen; Chenglong Liu; Changshui Xu
Journal:  Biomed Res Int       Date:  2016-06-20       Impact factor: 3.411

Review 9.  Cytokine Networks Dysregulation during HTLV-1 Infection and Associated Diseases.

Authors:  Nicolas Futsch; Gabriela Prates; Renaud Mahieux; Jorge Casseb; Hélène Dutartre
Journal:  Viruses       Date:  2018-12-05       Impact factor: 5.048

10.  Tumoral prostate shows different expression pattern of somatostatin receptor 2 (SSTR2) and phosphotyrosine phosphatase SHP-1 (PTPN6) according to tumor progression.

Authors:  Ariel Ernesto Cariaga-Martinez; María Angelica Lorenzati; Mario Alejandro Riera; Marisa Angelica Cubilla; Andrés De La Rossa; Ernesto Martín Giorgio; María Mercedes Tiscornia; Esteban Mariano Gimenez; María Eugenia Rojas; Bárbara Julieta Chaneton; Dora Isabel Rodríguez; Pedro Darío Zapata
Journal:  Adv Urol       Date:  2009-04-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.